2023
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Peer-Reviewed Original ResearchBalancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma
Potnis K, Huntington S. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma. Blood Advances 2023, 7: 2573-2574. PMID: 36745098, PMCID: PMC10242627, DOI: 10.1182/bloodadvances.2023009864.Peer-Reviewed Original ResearchCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2022
Artificial Intelligence in Breast Cancer Screening
Potnis K, Ross J, Aneja S, Gross C, Richman I. Artificial Intelligence in Breast Cancer Screening. JAMA Internal Medicine 2022, 182: 1306-1312. PMID: 36342705, PMCID: PMC10623674, DOI: 10.1001/jamainternmed.2022.4969.Peer-Reviewed Original ResearchWhen competition is not enough: leveraging US policies to curb oral anticancer drug costs
Potnis KC, Huntington SF. When competition is not enough: leveraging US policies to curb oral anticancer drug costs. The Lancet Oncology 2022, 23: 836-837. PMID: 35772451, DOI: 10.1016/s1470-2045(22)00297-2.Commentaries, Editorials and Letters
2020
Industry Payments and New Breast Cancer Screening Technology Use
Potnis KC, Gross CP, Richman IB. Industry Payments and New Breast Cancer Screening Technology Use. Journal Of General Internal Medicine 2020, 36: 1440-1442. PMID: 32468434, DOI: 10.1007/s11606-020-05771-9.Peer-Reviewed Original Research
2019
Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC, Flueckinger LB, Ha CI, Upadia J, Frush DP, Kishnani PS. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy. Mol Genet Metab 2019, 126: 157-161. PMID: 30448006, DOI: 10.1016/j.ymgme.2018.11.004.Peer-Reviewed Case Reports and Technical Notes
2018
Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum.
Potnis KC, Flueckinger LB, DeArmey SM, Alcalay RN, Cooney JW, Kishnani PS. Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. Mol Genet Metab Rep 2018, 17: 69-72. PMID: 30364808, DOI: 10.1016/j.ymgmr.2018.10.001.Peer-Reviewed Case Reports and Technical Notes